SEC Company Response from VIVOS INC (RDGL) (CIK 0001449349) (RDGL) — Feb 8, 2018
VIVOS INC (RDGL) (CIK 0001449349)
Date: Feb. 8, 2018 · CIK: 0001449349 · Accession: 0001415889-18-000198
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 000-53497, 333-216588
Referenced dates: April 6, 2017
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Attention: Pamela Long, Assistant Director Filed March 10, 2017 File No. 333-216588 Form 10-K for Fiscal Year Ended December 31, 2016 File No. 000-53497
Dear Ms. Long:
This letter is submitted on behalf of Vivos Inc, formerly Advanced Medical Isotope Corporation (the “Company”), together with the letter submitted by the Company on January 24, 2018, in response to comments of the staff of the Office of Manufacturing and Construction (the “Staff”) of the Securities and Exchange Commission (the “Commission”) with respect to the Company’s Registration Statement on Form S-1 (the “Registration Statement”), filed on March 10, 2017, and the Company’s Form 10-K for the fiscal year ended December 31, 2016 (the “10-K”), as set forth in your letter, dated April 6, 2017 (the “Comment Letter”) addressed to Dr. Michael Korenko, Acting Chief Executive Officer of the Company. In addition to Amendment No. 1 to the 10-K (the “10-K/A”) filed on January 25, 2018, the Company is filing Pre-Effective Amendment No. 1 to the Registration Statement (the “S-1/A”) contemporaneously with the submission of this letter to address the comments raised by the Staff in the Comment Letter, as more particularly set forth below.
For reference purposes, the Staff’s numbered comments have been reproduced in bold herein, with responses immediately following such comment. The responses provided herein are based upon information provided to Disclosure Law Group, a Professional Corporation, by the Company.
General
1.
You appear to be offering Units since you are registering the offer and sale of shares of common stock and warrants to purchase common stock which you state can only be purchased together. If you are offering Units, please revise your prospectus cover page, description of securities and otherwise throughout your registration statement to describe the Units. In addition, your fee table should cover the Units, common stock, warrants and the shares underlying the warrants. For additional guidance on the fee table, please refer to our Compliance and Disclosure Interpretations, Securities Act Rules, Questions 240.05 and 240.06, available on our website.
Response
Although the Company is offering shares of common stock together with common stock purchase warrants in the offering, the shares of common stock and warrants are immediately separable and are not intended to remain together as a single unit once the securities are in the possession of the purchaser. Both the cover page of the S-1/A and applicable sections throughout the prospectus contained within the S-1/A contain disclosure noting this distinction.
2.
Please clarify whether this is a best efforts offering with no minimum or a firm underwritten offering. To the extent that this is an underwritten offering, then please identify your lead underwriter(s) in your next amendment. We intend to defer further review of the filing until the registration statement is amended to include the name of the lead underwriter(s).
Response
The offering will be a firm underwritten offering, with ViewTrade Securities, Inc. acting as underwriter.
3.
It appears that you may be contemplating an at-the-market offering. You are not eligible under Rule 415 of the Securities Act of 1933 to conduct an at-the-market offering. Please revise your offering to sell shares at a fixed price for the duration of the offering, or advise. Similarly, you discuss increasing or decreasing the number of shares that you are offering. Please note that you may not increase the number of securities you are publicly offering without filing to register those additional securities, and revise accordingly.
Response
In response to Staff’s comment, all disclosure that appeared in the Registration Statement indicating the offering would be an at-the-market offering has been modified in the S-1/A to state that the offering will be conducted at a fixed price. In addition, all discussion of increasing or decreasing the number of shares that may be offered has been removed from the S-1/A.
4.
If you intend to conduct this offering on a best-efforts basis, then please revise your use of proceeds and dilution sections to provide the information assuming the sale of 25%, 50%, 75% and 100% of the offering.
Response
As noted in our response to comment 1 above, the offering will be a firm underwritten offering. As such, the revisions to the use of proceeds and dilution sections requested by the Staff do not appear in the S-1/A.
5.
Please provide disclosure requirements pursuant to Item 505 of Regulation S-K.
Response
In response to Staff’s comment, the disclosure required by Item 505 of Regulation S-K appears in the section titled “Determination of Offering Price” on page 60 of the prospectus contained within the S-1/A.
Outside Front Cover Page, page i
6.
Please limit the prospectus cover page to one page. See Item 50l (b) of Regulation S-K. Prospectus Summary, page 2
Response
The cover page of the prospectus contained in the S-1/A has been limited to one page.
7.
Please revise to disclose that you have received a going concern opinion from your auditor.
Response
Disclosure regarding the Company’s going concern opinion from its auditor now appears on the cover page of the prospectus contained within the S-1/A.
8.
We note your disclosure that the FDA classified RadioGel as a medical device. Please revise to clarify whether the FDA classified your RadioGel as a Class III medical device. Please briefly discuss the process and implications of being classified as Class I, Class II, and Class III.
Response
RadioGel is currently classified as a Class III medical device. In response to Staff’s comment, the Business section and the Business Overview section contained in note 1 to the financial statements for the years ended December 31, 2016 and 2015 in both the 10-K/A and S-1/A now contains disclosure clarifying this classification, as well as a brief discussion of the process surrounding the FDA’s classification of medical devices.
9.
We note that you repeatedly indicate that you intend to seek de novo review of your RadioGel. However, on page 8 you disclose that in 2015 the FDA notified you that your 2014 de novo application was not granted. Please reconcile. Please disclose what the company’s plans are given that the 2014 de novo application was not granted.
Response
Although the FDA denied the Company’s de novo petition in June 2015, the Company had a pre-submission informational meeting with the FDA in November 2015 and in August 2017. Based on feedback received during those meetings, the Company is currently developing test plans to address the issues raised by the FDA in connection with the Company’s previous submissions, and is preparing to re-submit its de novo petition to the FDA. Corrections have been made to disclosure in both the 10-K/A and the S-1/A to reconcile the inconsistent disclosure contained in the 10-K and the Registration Statement, and to disclose the Company’s plans for re-submission of its de novo petition to the FDA.
Risk Factors, page 7
The Company’s new products..., page 8
10.
We note here, and throughout your registration statement, that you discuss the Company’s product Y-90 RadioGel. We note that you mention Y-90 fast-Resorbable Polymer Seeds and Y-90 Polymer Topical Paste products in your risk factor section. Please clarify whether these products are currently in production and whether you are seeking FDA approval for these products. Please revise your business section as appropriate.
Response
The Company’s Y-90 fast-Resorbable Polymer Seeds and our Y-90 Polymer Topical Paste products are no longer in production. Accordingly, the Company is not seeking FDA approval for either product, nor was it doing so as of December 31, 2016. As a result, the relevant risk factor has been modified remove reference to each of these products in both the 10-K/A and the S-1/A.
The Company’s common stock is listed on the OTC Bulletin Board ..., page 14
11.
Please revise here and elsewhere to clarify that your stock is quoted on the OTC Pink.
Response
Revisions have been made to both the 10-K/A and the S-1/A as needed to clarify that the Company’s common stock is currently quoted on the OTC Pink.
Use of Proceeds, page 17
12.
You list the discharge of outstanding debt as a probable use of the proceeds of this offering. Please indicate the interest rate and maturity of the indebtedness to which you may apply these proceeds to and any other information required by Instruction 4 to Item 504 of Regulation S-K.
Response
The Use of Proceeds section in the prospectus contained within the S-1/A has been revised to include the disclosure required by Instruction 4 to Item 504 of Regulation S-K.
Dilution, page 21
13.
Please enhance your disclosures to clarify how you determine the net tangible book value of approximately $3 million as of December 31, 2016.
Response
The Dilution section in the prospectus contained within the S-1/A now sets forth the Company’s net tangible book value as of September 30, 2017, and contains a brief description as to how net tangible book value was calculated.
Management’s Discussion and Analysis of Financial Condition and Results of Operations, page 22
Revenue, page 22
14.
You disclose that consulting revenue generated $8,108 and $24,108 for the years ended December 31, 2016 and December 31, 2015, respectively, and that consulting revenues consisted of providing services to your company. Please clarify how providing services to your company generated revenues rather than resulting in operating expenses.
Response
The disclosure set forth in the 10-K and the prospectus contained within the Registration Statement referenced the provision of services to the Company in error, as the services were provided by the Company. The applicable disclosure has been revised in both the 10-K/A and the S-1/A to correct the error.
Business, page 29
Overview, page 29
15.
Please update your disclosure in this section, in your summary, and elsewhere in your document as appropriate to disclose (i) the initial FDA submission and outcome, (ii) your 2014 de novo submission and outcome; and (iii) the status of any other submissions. See Item 10 I (h)(4)(iii) of Regulation S-K. Please revise to state clearly that in the event the FDA denies your initial 510(k) application and subsequently determines during the de novo review that your device cannot be classified as a Class I or Class II device, you will then need to submit a PMA application to obtain the necessary regulatory approval.
Response
In response to Staff’s comment, the Company has included a new section entitled “Regulatory History” in the Business section and the section titled Business Overview in note 1 to the financial statements for the year ended December 31, 2016 and 2015 in both the 10-K/A and the S-1/A that describes the status of the Company’s progress with the FDA.
Veterinary Sector, page 34
16.
Please disclose the role of the Veterinary Advisory Board in the operation of your business.
Response
The Company has provided disclosure in the Business section, under the heading “Principal Markets, Veterinary Sector” in both the 10-K/A and the prospectus contained within the S-1/A in response to the Staff’s comment.
17.
Please disclose the material terms of your engagement with each of the four university veterinarian hospitals.
Response
Both the 10-K/A and the S-1/A now contain disclosure regarding the material terms of the engagements with each of the four universities.
18.
We note your disclosure that Dr. Villalobos has agreed that her private clinic will be the first to implement the company’s veterinary therapies. Please disclose the material terms of your arrangement with Dr. Villalobos.
Response
As of December 31, 2016, the Company believed Dr. Villalobos would be the first to utilize RadioGel™ in her private practice, and would be introducing management to other clinics. However, these activities have yet to occur and this disclosure has been removed from both the 10-K/A and the S-1/A.
Government Regulation, page 35
19.
Please significantly expand the disclosure in this section to discuss in detail the material government regulations that are applicable to your business, including standard processing times for approval to test and market your products. In addition, provide an anticipated timeline for any submissions to the FDA and other anticipated actions by you before regulatory bodies. We note your disclosure on page 8 that the company will explore steps toward seeking approval for the device as a Class III medical device. Please discuss in detail the processes and anticipated costs associated with seeking this approval.
Response
Both currently and as of December 31, 2016, the Company continues to pursue approval for RadioGel™ as a Class II medical device, rather than as a Class III medical device. The Company has revised the Government Regulation section contained within the Business section of both the 10-K/A and the prospectus contained within the S-1/A in response to the Staff’s comment.
Raw Materials, page 35
20.
Please expand your disclosure to provide the availability and the names of your principal suppliers of raw materials. We note your disclosure that some of your products require purchasing raw materials from a limited number of suppliers. Sec Item 10l(h)(4)(v) of Regulation S-K.
Response
The disclosure provided under in the Business section of both the 10-K/A and the prospectus contained within the S-1/A under the heading “Raw Materials” now contains a more detailed description of the Company’s principal suppliers of raw materials.
Management, page 37
Identification of Significant Employees and Consultants, page 38
21.
Please provide for Dr. Alice Villalobos and all other “Veterinarian Advisory Board” and “Medical Advisory Board” members the appropriate biographical disclosure required by Item 401 (c) of Regulation S-K.
Response
The Company has included biographical disclosure for those individuals who were members of the Veterinarian Advisory Board and Medical Advisory Board as of December 31, 2016 in the 10-K/A and as of December 31, 2017 in the S-1/A.
Executive Compensation, page 39
22.
Please revise your Summary Compensation Table to be in the format required by Item 402(n) of Regulation S-K.
Response
The Company has revised the Summary Compensation Table in both the 10-K/A and the prospectus contained within the S-1/A to be in the format required by Item 402(n) of Regulation S-K.
23.
We note your disclosure on options granted to the named executive officers in footnotes 3 and 5 to your Summary Compensation Table. Please include in your table the aggregate grant date fair value of the options computed in accordance with FASB ASC Topic 718. Please refer to Item 402(n)(2)(vi) of Regulation S-K and the instructions to that item.
Response
The Summary Compensation Table in the 10-K/A and the S-1/A now includes the aggregate grant date fair value of the options granted to the Company’s named executive officers, calculated in accordance with FASB ASC Topic 718, as requested by the Staff.
Compensation of Directors, page 40
24.
You state that non-employee directors were not paid any compensation during FYE 2016. You also disclose, however, that during June 2016 you granted to Directors Cadwell and Clement options to purchase 100,000 shares at an exercise price of $1.00 per share. Please reconcile your disclosure and provide the director compensation table required by Item 402(r)(l) of Regulation S-K.
Response
The C
Show Raw Text
CORRESP 1 filename1.htm Vivos Inc. - FORM correspondence February 8, 2018 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Pamela Long, Assistant Director RE: Vivos Inc (formerly Advanced Medical Isotope Corporation) Registration Statement on Form S-1 Filed March 10, 2017 File No. 333-216588 Form 10-K for Fiscal Year Ended December 31, 2016 File No. 000-53497 Dear Ms. Long: This letter is submitted on behalf of Vivos Inc, formerly Advanced Medical Isotope Corporation (the “Company”), together with the letter submitted by the Company on January 24, 2018, in response to comments of the staff of the Office of Manufacturing and Construction (the “Staff”) of the Securities and Exchange Commission (the “Commission”) with respect to the Company’s Registration Statement on Form S-1 (the “Registration Statement”), filed on March 10, 2017, and the Company’s Form 10-K for the fiscal year ended December 31, 2016 (the “10-K”), as set forth in your letter, dated April 6, 2017 (the “Comment Letter”) addressed to Dr. Michael Korenko, Acting Chief Executive Officer of the Company. In addition to Amendment No. 1 to the 10-K (the “10-K/A”) filed on January 25, 2018, the Company is filing Pre-Effective Amendment No. 1 to the Registration Statement (the “S-1/A”) contemporaneously with the submission of this letter to address the comments raised by the Staff in the Comment Letter, as more particularly set forth below. For reference purposes, the Staff’s numbered comments have been reproduced in bold herein, with responses immediately following such comment. The responses provided herein are based upon information provided to Disclosure Law Group, a Professional Corporation, by the Company. General 1. You appear to be offering Units since you are registering the offer and sale of shares of common stock and warrants to purchase common stock which you state can only be purchased together. If you are offering Units, please revise your prospectus cover page, description of securities and otherwise throughout your registration statement to describe the Units. In addition, your fee table should cover the Units, common stock, warrants and the shares underlying the warrants. For additional guidance on the fee table, please refer to our Compliance and Disclosure Interpretations, Securities Act Rules, Questions 240.05 and 240.06, available on our website. Response Although the Company is offering shares of common stock together with common stock purchase warrants in the offering, the shares of common stock and warrants are immediately separable and are not intended to remain together as a single unit once the securities are in the possession of the purchaser. Both the cover page of the S-1/A and applicable sections throughout the prospectus contained within the S-1/A contain disclosure noting this distinction. 2. Please clarify whether this is a best efforts offering with no minimum or a firm underwritten offering. To the extent that this is an underwritten offering, then please identify your lead underwriter(s) in your next amendment. We intend to defer further review of the filing until the registration statement is amended to include the name of the lead underwriter(s). Response The offering will be a firm underwritten offering, with ViewTrade Securities, Inc. acting as underwriter. 3. It appears that you may be contemplating an at-the-market offering. You are not eligible under Rule 415 of the Securities Act of 1933 to conduct an at-the-market offering. Please revise your offering to sell shares at a fixed price for the duration of the offering, or advise. Similarly, you discuss increasing or decreasing the number of shares that you are offering. Please note that you may not increase the number of securities you are publicly offering without filing to register those additional securities, and revise accordingly. Response In response to Staff’s comment, all disclosure that appeared in the Registration Statement indicating the offering would be an at-the-market offering has been modified in the S-1/A to state that the offering will be conducted at a fixed price. In addition, all discussion of increasing or decreasing the number of shares that may be offered has been removed from the S-1/A. 4. If you intend to conduct this offering on a best-efforts basis, then please revise your use of proceeds and dilution sections to provide the information assuming the sale of 25%, 50%, 75% and 100% of the offering. Response As noted in our response to comment 1 above, the offering will be a firm underwritten offering. As such, the revisions to the use of proceeds and dilution sections requested by the Staff do not appear in the S-1/A. 5. Please provide disclosure requirements pursuant to Item 505 of Regulation S-K. Response In response to Staff’s comment, the disclosure required by Item 505 of Regulation S-K appears in the section titled “Determination of Offering Price” on page 60 of the prospectus contained within the S-1/A. Outside Front Cover Page, page i 6. Please limit the prospectus cover page to one page. See Item 50l (b) of Regulation S-K. Prospectus Summary, page 2 Response The cover page of the prospectus contained in the S-1/A has been limited to one page. 7. Please revise to disclose that you have received a going concern opinion from your auditor. Response Disclosure regarding the Company’s going concern opinion from its auditor now appears on the cover page of the prospectus contained within the S-1/A. 8. We note your disclosure that the FDA classified RadioGel as a medical device. Please revise to clarify whether the FDA classified your RadioGel as a Class III medical device. Please briefly discuss the process and implications of being classified as Class I, Class II, and Class III. Response RadioGel is currently classified as a Class III medical device. In response to Staff’s comment, the Business section and the Business Overview section contained in note 1 to the financial statements for the years ended December 31, 2016 and 2015 in both the 10-K/A and S-1/A now contains disclosure clarifying this classification, as well as a brief discussion of the process surrounding the FDA’s classification of medical devices. 9. We note that you repeatedly indicate that you intend to seek de novo review of your RadioGel. However, on page 8 you disclose that in 2015 the FDA notified you that your 2014 de novo application was not granted. Please reconcile. Please disclose what the company’s plans are given that the 2014 de novo application was not granted. Response Although the FDA denied the Company’s de novo petition in June 2015, the Company had a pre-submission informational meeting with the FDA in November 2015 and in August 2017. Based on feedback received during those meetings, the Company is currently developing test plans to address the issues raised by the FDA in connection with the Company’s previous submissions, and is preparing to re-submit its de novo petition to the FDA. Corrections have been made to disclosure in both the 10-K/A and the S-1/A to reconcile the inconsistent disclosure contained in the 10-K and the Registration Statement, and to disclose the Company’s plans for re-submission of its de novo petition to the FDA. Risk Factors, page 7 The Company’s new products..., page 8 10. We note here, and throughout your registration statement, that you discuss the Company’s product Y-90 RadioGel. We note that you mention Y-90 fast-Resorbable Polymer Seeds and Y-90 Polymer Topical Paste products in your risk factor section. Please clarify whether these products are currently in production and whether you are seeking FDA approval for these products. Please revise your business section as appropriate. Response The Company’s Y-90 fast-Resorbable Polymer Seeds and our Y-90 Polymer Topical Paste products are no longer in production. Accordingly, the Company is not seeking FDA approval for either product, nor was it doing so as of December 31, 2016. As a result, the relevant risk factor has been modified remove reference to each of these products in both the 10-K/A and the S-1/A. The Company’s common stock is listed on the OTC Bulletin Board ..., page 14 11. Please revise here and elsewhere to clarify that your stock is quoted on the OTC Pink. Response Revisions have been made to both the 10-K/A and the S-1/A as needed to clarify that the Company’s common stock is currently quoted on the OTC Pink. Use of Proceeds, page 17 12. You list the discharge of outstanding debt as a probable use of the proceeds of this offering. Please indicate the interest rate and maturity of the indebtedness to which you may apply these proceeds to and any other information required by Instruction 4 to Item 504 of Regulation S-K. Response The Use of Proceeds section in the prospectus contained within the S-1/A has been revised to include the disclosure required by Instruction 4 to Item 504 of Regulation S-K. Dilution, page 21 13. Please enhance your disclosures to clarify how you determine the net tangible book value of approximately $3 million as of December 31, 2016. Response The Dilution section in the prospectus contained within the S-1/A now sets forth the Company’s net tangible book value as of September 30, 2017, and contains a brief description as to how net tangible book value was calculated. Management’s Discussion and Analysis of Financial Condition and Results of Operations, page 22 Revenue, page 22 14. You disclose that consulting revenue generated $8,108 and $24,108 for the years ended December 31, 2016 and December 31, 2015, respectively, and that consulting revenues consisted of providing services to your company. Please clarify how providing services to your company generated revenues rather than resulting in operating expenses. Response The disclosure set forth in the 10-K and the prospectus contained within the Registration Statement referenced the provision of services to the Company in error, as the services were provided by the Company. The applicable disclosure has been revised in both the 10-K/A and the S-1/A to correct the error. Business, page 29 Overview, page 29 15. Please update your disclosure in this section, in your summary, and elsewhere in your document as appropriate to disclose (i) the initial FDA submission and outcome, (ii) your 2014 de novo submission and outcome; and (iii) the status of any other submissions. See Item 10 I (h)(4)(iii) of Regulation S-K. Please revise to state clearly that in the event the FDA denies your initial 510(k) application and subsequently determines during the de novo review that your device cannot be classified as a Class I or Class II device, you will then need to submit a PMA application to obtain the necessary regulatory approval. Response In response to Staff’s comment, the Company has included a new section entitled “Regulatory History” in the Business section and the section titled Business Overview in note 1 to the financial statements for the year ended December 31, 2016 and 2015 in both the 10-K/A and the S-1/A that describes the status of the Company’s progress with the FDA. Veterinary Sector, page 34 16. Please disclose the role of the Veterinary Advisory Board in the operation of your business. Response The Company has provided disclosure in the Business section, under the heading “Principal Markets, Veterinary Sector” in both the 10-K/A and the prospectus contained within the S-1/A in response to the Staff’s comment. 17. Please disclose the material terms of your engagement with each of the four university veterinarian hospitals. Response Both the 10-K/A and the S-1/A now contain disclosure regarding the material terms of the engagements with each of the four universities. 18. We note your disclosure that Dr. Villalobos has agreed that her private clinic will be the first to implement the company’s veterinary therapies. Please disclose the material terms of your arrangement with Dr. Villalobos. Response As of December 31, 2016, the Company believed Dr. Villalobos would be the first to utilize RadioGel™ in her private practice, and would be introducing management to other clinics. However, these activities have yet to occur and this disclosure has been removed from both the 10-K/A and the S-1/A. Government Regulation, page 35 19. Please significantly expand the disclosure in this section to discuss in detail the material government regulations that are applicable to your business, including standard processing times for approval to test and market your products. In addition, provide an anticipated timeline for any submissions to the FDA and other anticipated actions by you before regulatory bodies. We note your disclosure on page 8 that the company will explore steps toward seeking approval for the device as a Class III medical device. Please discuss in detail the processes and anticipated costs associated with seeking this approval. Response Both currently and as of December 31, 2016, the Company continues to pursue approval for RadioGel™ as a Class II medical device, rather than as a Class III medical device. The Company has revised the Government Regulation section contained within the Business section of both the 10-K/A and the prospectus contained within the S-1/A in response to the Staff’s comment. Raw Materials, page 35 20. Please expand your disclosure to provide the availability and the names of your principal suppliers of raw materials. We note your disclosure that some of your products require purchasing raw materials from a limited number of suppliers. Sec Item 10l(h)(4)(v) of Regulation S-K. Response The disclosure provided under in the Business section of both the 10-K/A and the prospectus contained within the S-1/A under the heading “Raw Materials” now contains a more detailed description of the Company’s principal suppliers of raw materials. Management, page 37 Identification of Significant Employees and Consultants, page 38 21. Please provide for Dr. Alice Villalobos and all other “Veterinarian Advisory Board” and “Medical Advisory Board” members the appropriate biographical disclosure required by Item 401 (c) of Regulation S-K. Response The Company has included biographical disclosure for those individuals who were members of the Veterinarian Advisory Board and Medical Advisory Board as of December 31, 2016 in the 10-K/A and as of December 31, 2017 in the S-1/A. Executive Compensation, page 39 22. Please revise your Summary Compensation Table to be in the format required by Item 402(n) of Regulation S-K. Response The Company has revised the Summary Compensation Table in both the 10-K/A and the prospectus contained within the S-1/A to be in the format required by Item 402(n) of Regulation S-K. 23. We note your disclosure on options granted to the named executive officers in footnotes 3 and 5 to your Summary Compensation Table. Please include in your table the aggregate grant date fair value of the options computed in accordance with FASB ASC Topic 718. Please refer to Item 402(n)(2)(vi) of Regulation S-K and the instructions to that item. Response The Summary Compensation Table in the 10-K/A and the S-1/A now includes the aggregate grant date fair value of the options granted to the Company’s named executive officers, calculated in accordance with FASB ASC Topic 718, as requested by the Staff. Compensation of Directors, page 40 24. You state that non-employee directors were not paid any compensation during FYE 2016. You also disclose, however, that during June 2016 you granted to Directors Cadwell and Clement options to purchase 100,000 shares at an exercise price of $1.00 per share. Please reconcile your disclosure and provide the director compensation table required by Item 402(r)(l) of Regulation S-K. Response The C